Complications of Multiple Myeloma

Hematology/Oncology Clinics of North America

Volumn 21, Issue 6, 2007, Pages 1231-1246

  Bladé, Joan ^a   Rosiñol, Laura ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHOGLYCERATE MUTASE; BORTEZOMIB; CHLORAMBUCIL; CLODRONIC ACID; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; HYDROCORTISONE; IMMUNOGLOBULIN; IRON; IRON SACCHARATE; LEVOFLOXACIN; MELPHALAN; METHOTREXATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PAMIDRONIC ACID; PENICILLIN G; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; RITUXIMAB; TELITHROMYCIN; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE; ZOLEDRONIC ACID;

AMYLOIDOSIS; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ATAXIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOTRANSPLANTATION; BACTERIAL INFECTION; BLEEDING DISORDER; BONE DISEASE; BONE MARROW DEPRESSION; BONE NECROSIS; BRAIN DISEASE; CALCIUM BLOOD LEVEL; CONSTIPATION; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSERYTHROPOIESIS; ENTEROBACTER; ERYTHROCYTE TRANSFUSION; ESCHERICHIA COLI; FANCONI RENOTUBULAR SYNDROME; FREQUENCY ANALYSIS; GRANULOCYTOPENIA; HAEMOPHILUS INFLUENZAE; HEART ATRIUM ARRHYTHMIA; HEMATOLOGIC DISEASE; HUMAN; HYPERCALCEMIA; HYPERVISCOSITY SYNDROME; IMMUNOGLOBULIN DEPOSITION; INCIDENCE; INFECTION; INFECTION PREVENTION; INFECTION SENSITIVITY; INFECTIOUS COMPLICATION; JAW DISEASE; KIDNEY FAILURE; KIDNEY TUBULE EXCRETION; KLEBSIELLA; LEUKEMOGENESIS; LIGHT CHAIN; LOADING DRUG DOSE; MENINGOCELE; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; NERVE ROOT COMPRESSION; NEUROLOGICAL COMPLICATION; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PAIN; PARALYTIC ILEUS; PARESTHESIA; PATHOGENESIS; PATHOLOGIC FRACTURE; PERIPHERAL NEUROPATHY; PLASMACYTOMA; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEUS; PSEUDOMONAS; RENAL REPLACEMENT THERAPY; REVIEW; SPINAL CORD COMPRESSION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT INDICATION; TREMOR; TUBULAR DYSFUNCTION; WALDENSTROEM MACROGLOBULINEMIA;

BACTERIAL INFECTIONS; HUMANS; MULTIPLE MYELOMA; OSTEOLYSIS; PANCYTOPENIA; PERIPHERAL NERVOUS SYSTEM DISEASES; RENAL INSUFFICIENCY;

EID: 35748964475     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2007.08.006     Document Type: Review

References (72)

1. Alexanian R., Barlogie B., and Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 150 (1990) 1693-1695
2. Bladé J., Fernández-Lama P., Bosch F., et al. Renal failure in multiple myeloma. Presenting features and predictors of outcome in a series of 94 patients. Arch Intern Med 158 (1998) 1889-1893
3. Bladé J. Management of renal, hematologic, and infectious complications. In: Malpas J.S., Bergsagel D.E., Kyle R.A., et al. (Eds). Myeloma: biology and management. 3rd edition (2004), Saunders, Elsevier Inc., Philadelphia 251-267
4. Hill G.S., Morel-Maroger L., Méry J.P., et al. Renal lesions in multiple myeloma: their relationship to associated protein abnormalities. Am J Kidney Dis 4 (1983) 423-438
5. Sanders P.W. Pathogenesis and treatment of myeloma kidney. J Lab Clin Med 124 (1994) 484-488
6. Johnson W.J., Kyle R.A., Pineda A.A., et al. Treatment of renal failure associated to multiple myeloma. Arch Intern Med 150 (1990) 863-869
7. Kyle R.A., and Greipp P.R. "Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients. N Engl J Med 306 (1982) 564-567
8. Torra R., Bladé J., Cases A., et al. Patients with multiple myeloma and renal failure requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 91 (1995) 854-859
9. Bladé J., Lust J.A., and Kyle R.A. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 83 patients. J Clin Oncol 12 (1994) 2398-2404
10. Randall R.E., Williamson W.C., Mullinax F., et al. Manifestations of systemic light chain deposition. Am J Med 60 (1976) 293-299
11. Dhodapkar M.V., Merlini G., and Solomon A. Biology and therapy of immunoglobulin deposition diseases. Hematol Oncol Clin North Am 11 (1997) 89-110
12. Ma C.X., Lacy M.Q., Rompala J.F., et al. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood 104 (2004) 40-42
13. Bernstein S.P., and Humes D.H. Reversible renal insufficiency in multiple myeloma. Arch Intern Med 142 (1982) 2083-2086
14. Cavo M., Baccarani M., Galieni P., et al. Renal failure in multiple myeloma: a study of the presenting findings, response to treatment, and prognosis in 26 patients. Nouv Rev Fr Hematol 28 (1986) 147-152
15. Cohen D.J., Sherman W., and Osserman E.F. Acute renal failure in patients with multiple myeloma. Am J Med 76 (1984) 247-256
16. Iggo N., Palmer A.B., Severn A., et al. Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment. Q J Med 270 (1989) 903-910
17. Korzets A., Tam F., Russell G., et al. The role of continuous ambulatory peritoneal dialysis in end-stage renal failure due to multiple myeloma. Am J Kidney Dis 6 (1990) 216-223
18. Chanan-Khan A.A., Kaufman J.L., Metha J., et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 109 (2007) 2604-2606
19. Badros A., Barlogie B., Siegel E., et al. Results of autologous stem cell transplantation in multiple myeloma patients with renal failure. Br J Haematol 114 (2001) 822-829
20. Pasquali S., Casanova S., Zuchelli A., et al. Long-term survival in patients with acute and severe renal failure due to multiple myeloma. Clin Nephrol 34 (1990) 247-254
21. Misiani R., Tiraboschi G., Mingardi G., et al. Management of myeloma kidney: an anti-light-chain approach. Am J Kidney Dis 10 (1987) 28-33
22. Pozzi C., Pasqualli S., Donini U., et al. Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: review of 50 cases. Clin Nephrol 28 (1987) 1-9
23. Clark W.F., Stewart A.K., Rock G.A., et al. Plasma exchange when myeloma presents as acute renal failure. A randomized, controlled trial. Ann Intern Med 143 (2005) 777-784
24. Kyle R.A., Gertz M.A., Witzig T.E., et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78 (2003) 21-33
25. Bladé J., San Miguel J.F., Fontanillas M., et al. Initial treatment of multiple myeloma: long-term results in 914 patients. Hematol J 2 (2001) 272-278
26. Mecharchand J. Management of haematological complications of myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, et al, editors. Myeloma: biology and management. 2nd edition. Oxford: Oxford University Press. p. 332-57.
27. Berguin Y., Yerna M., Loo M., et al. Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol 82 (1992) 648-653
28. Rizzo J.D., Lichtin A.E., Woolf S.H., et al. Use of epoietin in patients with cancer: evidence-based clinical pactice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 100 (2002) 2303-2320
29. Rizzo J.D., Lichtin A.E., Woolf S.H., et al. Use of epoietin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2 (2002) 40-83
30. Bergsagel D.E., Bailey A.J., Langley G.R., et al. The chemotherapy of plasma cell myeloma and the incidence of acute leukemia. N Engl J Med 301 (1979) 743-748
31. Bergsagel D.E. Plasma cell neoplasms and acute leukemia. Clin Haematol 11 (1982) 221-234
32. Finnish Leukemia Group. Acute leukemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukemia Group study. Eur J Haematol 65 (2000) 123-127
33. Cuzick J., Erskine S., Edelman D., et al. A comparison of the incidence of myelodysplastic syndrome and acute leukemia following melphalan and cyclophosphamide treatment for multiple myeloma. Br J Cancer 55 (1987) 523-529
34. Govindarajan R., Jagannath S., Flick J.T., et al. Preceding standard therapy is the likely cause of MDS after autotransplants in multiple myeloma. Br J Haematol 95 (1996) 349-353
35. Kelleher P., and Chapel H. Infections: principle of prevention and therapy. In: Metha J., and Singhal S. (Eds). Myeloma (2002), Martin Dunitz Ldt, London 223-239
36. Savage D.G., Lindenbaum J., and Garret T.J. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med 96 (1982) 47-50
37. Meyers B.R., Hirschman S.Z., and Axelrod J.A. Current pattern of infection in multiple myeloma. Am J Med 52 (1972) 87-92
38. Shaikh B.S., Lombard R.M., Appelbaum P.C., et al. Changing pattern of infection in patients with multiple myeloma. Oncology 39 (1982) 78-82
39. Hargreaves R.M., Lea J.R., Griffiths H., et al. Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol 48 (1995) 260-266
40. Perri R.T., Hebbel R.P., and Oken M.M. Influence of treatment and response status on infection in multiple myeloma. Am J Med 71 (1981) 935-940
41. Snowden L., Gibson J., and Joshua D.E. Frequency of infection in plateau-phase multiple myeloma. Lancet 344 (1994) 262 [Letter to the Editor]
42. Oken M.M., Pomeroy C., and Weisdorf D. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 100 (1996) 624-628
43. Hoen B., Kessler M., Hestin D., et al. Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicenter prospective survey. Nephrol Dial Transplant 10 (1995) 377-381
44. Salmon S.E., Samal B.A., Hayes D.M., et al. Role of gammaglobulin for immunoprophylaxis in multiple myeloma. N Engl J Med 277 (1967) 1336-1340
45. Stashenko P., Dewhirts F.E., Peros W.J., et al. Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol 138 (1987) 1464-1468
46. Lacy M.Q., Donovan K.A., Heimbach J.K., et al. Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 93 (1999) 300-305
47. Lust J.A., and Donovan K.A. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 13 (1999) 1117-1125
48. Klein B., Zhang X.G., Lu Z.Y., et al. Interleukin-6 in human multiple myeloma. Blood 85 (1995) 863-872
49. Li J., Sarosi I., Yan X.-Q., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA (2000) 1566-1571
50. Major P., Lortholary A., Hon J., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19 (2001) 558-567
51. Lahtinen R., Laakso M., Palva I., et al. Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340 (1992) 1049-1052
52. McCloskey E.V., MacLennan I.C., Drayson M.T., et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 100 (1998) 317-325
53. Berenson J.R., Lichtenstein A., Porter L., et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334 (1996) 488-493
54. Rosen L.S., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double blinded, comparative trial. Cancer J 7 (2001) 377-387
55. Berenson J.R., Hillner B.E., Kyle R.A., et al. American Society of Clinical Oncology practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20 (2002) 3719-3736
56. Lacy M.Q., Dispenzieri A., Gertz M.A., et al. Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81 (2006) 1047-1053
57. Durie B.G.M., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. [letter]. N Engl J Med 353 (2005) 99-100
58. Badros A., Weikel D., Salama A., et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24 (2006) 945-952
59. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 (2005) 8580-8587
60. Woo S.B., Hellstein J.W., and Kalmar J.R. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144 (2006) 753-761
61. Gawler J. Neurological manifestations of myeloma and their management. In: Malpas J.S., Bergsagel D.E., Kyle R.A., et al. (Eds). Myeloma: biology and management. 3rd edition (2004), Saunders, Elsevier Inc., Philadelphia 269-293
62. Henson R.A., and Urich H. Cancer and nervous system. The neurological manifestations of systemic malignant disease (1982), Blackwell Scientific Publications, Oxford
63. Posner J.B. Back pain and epidural spinal cord compression. Med Clin North Am 71 (1987) 185-205
64. Woodruff R.K., and Ireton H.J.C. Multiple nerve palsies as the presenting feature of meningeal myelomatosis. Cancer 49 (1982) 1710-1712
65. Spaar F.W. Paraproteinemias and multiple myeloma. In: Bryn V. (Ed). Handbook of clinical neurology (1980), Elsevier North Holland Biomedical Press, Amsterdan 131-179
66. Fassas A., Ward S., Muwalla F., et al. Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma 45 (2004) 291-300
67. Latov N., Hays A.P., and Sherman W.H. Peripheral neuropathy associated to antiMAG antibodies. Crit Rev Neurobiol 3 (1988) 301-332
68. Nobile-Orazio E., Meucci N., Baldini L., et al. Long term prognosis of neuropathy associated with antiMAG IgM M-proteins and its relationship to immune therapies. Brain 123 (2000) 710-717
69. Latov N., and Sherman W.H. Therapy of neuropathy associated with antiMAG IgM monoclonal gammopathy with Rituxan. Neurology 52 Suppl 2 (1999) a551
70. Levine T.D., and Pestronk A. IgM antibody related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 52 (1999) 1701-1704
71. Cibeira M.T., Rosiñol L., Ramiro L., et al. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. Eur J Haematol 77 (2006) 486-492
72. Richardson P.G., Briemberg H., Jagannath S., et al. Frequency, characteristics and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24 (2006) 3113-3120